Substituted benzofuranylpiperidine as a nootropic agent

Details Substituted benzofuranylpiperidine as a nootropic agent Substituted benzofuranylpiperidine as a nootropic agent

1994-01-13

1995-10-03

Killos, Paul J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A01N 4340

Patent

active

054552540

ABSTRACT:
4-(7-Bromo-5-methoxybenzofuran-2-yl)piperidine (brofarornine) of formula I ##STR1## and its pharmaceutically acceptable salts can be used as active ingredients in medicaments for retarding the degeneration of nerve cells that accompanies degenerative nerve disorders, and as a nootropic agent for treating disorders that are responsive to treatment with nootropic agents.

REFERENCES:
patent: 4210655 (1980-07-01), Schenker et al.
patent: 4600719 (1986-07-01), Schenker et al.
patent: 4829067 (1989-05-01), Iijima et al.
patent: 4971995 (1990-11-01), Schoofs et al.
patent: 4977159 (1990-12-01), Sevrin et al.
patent: 4999382 (1991-03-01), Wurtman
patent: 5011849 (1991-04-01), Gassner et al.
Chem. Abst. 109:143172 1988.
Chem. Abst. 106:4786 1986.
Chem Abst. 105:203054 1985.
Chem Abst. 111:225228r, 1989, "The Reversible MAO Inhibitor Brofaromine Inhibits Serotonin Uptake in Vivo".
Chem Abst. 115:201791a, 1991 "The Inhibition of Monoamine Oxidase by Brofaromine".
Chem Abst. 114:221228e, 1991 "Some Central Effects of Brofaromine Given Repeatedly are Phase Dependent".
Bieck, et al, J. Neural Transm 1989 [Suppl.] 28:21-31.
Am. J. Psychiatry 142, (1985) pp. 763-764 Abstract.
Schiwy et al, J. Neural Transm 1989 [Suppl.] 28;33-44.
Liebowitz et al; Arch. Gen Psychiatry 42, 729-736; Jul. 1985.
Liebowitz et al; Acta Psychiatr Scand. 1990:Suppl. 260:29-34.
Liebowitz, et al; J. Clin. Psychiatry 49:7 pp. 252-257; Jul. 1988.
Davidson et al; Arch Gen Psychiatry, Mar. 1990 pp. 259-266.
Silver et al; J. Clin Psychiatry 51:10 (Suppl) pp. 33-38 Oct. 1990.
Friedman; J. Traumatic Stress 41(1), 67-91, 1991.
Kyburz; Drug News Perspect 3(10), 592-599, Dec. 1990.
Tariot et al, Psychopharmacology 91(4) 489-495, 1987.
Drugs of the Future; Brofaromine; 10, No. 5, 371-373; 1985.
Nahunek et al; Act. Nerv. Super. 32(3), 230-231, 1990.
J. Neural Transm [P-D Sect] (1989) 1:82-83.
The Merck Index, 11th Ed. 1989, Piracetam Entry 7459, p. 1189.
Pharma Structures-4 Printout for CGS 5649B Sep. 1989.
Pharmastructures-4 Printout for Modobemide Jun. 1990.
Mondadori et al; Behavioral and Neural Biology 57, 149-156 (1992).
Derwent Atstr. BPS 22 32 35 60 91-07627 of Fund. Am. Clin. Pharmacol., No. 5, 588, 1990; Berlin et al.
Fawcett et al; Derwent Abstr. TS 32 35 64 91-25518 J. Clin Psychopharmacol. 11, No. 2, 127-132, 1991.
Derwent Abstr. TS 26 32 35 85-35035 or Jenike; Am. J. Psychiatry 142, No. 6, 763-64, 1985.
Derwent Abstr. 35 67 69 88-30603 of Small; J. Clin Psychiatry 49, No. 5, Suppl. 8-13, 1988.
Derwent Abstr. T 32 84-49695 of Jenike; J. Am. Geriatr. Soc. 32, No. 8, 571-575, 1984.
Linnoila et al; Acta Psychiatr. Scand., Suppl. 308 vol. 68, 175-181, 1983.
Weingartner et al; Science vol. 221, 427-474 (1983).
Warrington et al; Br. J. Clin. Pharmacol. (1984), 18, 549-557.
Curran et al; Psychopharmacology (1986) 89:360-363.
Curran et al; Psychopharmacology (1988) 95:520-527.
Saletu et al; J. Neural Transmission 49, 63-86 (1980).
Eckardt et al; 15th Collegium Internationale Neuro-Psychopharmacologicum, 1986, S-21, p. 55-57.
Martin et al; Arch Gen Psychiatry; vol. 46, 617-621 (Jul. 1989).
Moskowitz and Burns; Prog. Neuro-Psychopharmacol. and Biol. Psychiat. 1988, vol. 12, 783-792.
Ahlers and Best; Journal of Comparative and Psysiological Psychology, 1972, vol. 79, No. 3, 371-376.
Waldmeier and Stocklin, European Journal of Pharmacology vol. 169, Nos. 2/3, Oct. 10, 1989, 197-204.
Waldmeier and Stocklin; European Journal of Pharmacology 180 (1990) 297-304.
Waldmeir et al; "Reversible Monoamine Oxidase Inhibition: Relation Between Effects on Enzymatic Activity Measured Ex14 Vivo and on Amine Metabolism" Monoamine Oxidase and Disease (American Press London 1984).
Mondadori et al; Psychopharmacology (1992) 109:383-389.
Mondadori et al; Clinical Neuropharmacology, vol. 9, Suppl. 3, pp. 527-538, 1986.
Mangoni et al; Drug Development Research 14:217-222 (1988).
Mondadori et al; Psychopharmacology (1992) 108:11-15.
Villardita et al; J. Neural Transm. (1987) [Suppl9 24:293-298.
Ban et al; Prog Neuro-Psychopharmacol. & Biol. Psychiat. 1990, vol. 14, pp. 525-551.
Davis et al; New England Journal of Medicine, vol. 327, No. 18, Oct. 29, 1992, pp. 1253-1259.
Harrell et al; Neurology 1990; 40:1350-1354.
Guillaumel et al; Eur. J. Med. Chem. -Chem Ther. 1983, vol. 18, No. 5, pp. 431-436.
Gueremy et al; J. Med. Chem 1980, 23, 1306-1310.

Affiliated with

Also associated with

Rating

Substituted benzofuranylpiperidine as a nootropic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted benzofuranylpiperidine as a nootropic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted benzofuranylpiperidine as a nootropic agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1077664